SIGN 163: Prevention and management of venous thromboembolism in COVID-19

Zusammenfassung

Prevention and management of venous thromboembolism in patients with COVID-19 Rapid guideline A national clinical guideline December 2021 SIGN163 Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta-analyses, systematic reviews, or RCTs with a high risk of bias 2 ++

Kerninformationen

R For ‘conditional’ recommendations on interventions that should be ‘considered’, the guideline development group is confident that the intervention will do more good than harm for most patients. The choice of intervention is therefore more likely to vary depending on a person’s values and prefere...

Prevention and management of venous thromboembolism in COVID-19. Edinburgh: SIGN; 2021. (SIGN publication 163). [December 2021]. Available from URL: http://www.sign.ac.uk This document is licensed under the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International Licence. This al...

A meta-analysis of studies of rates of vascular thrombosis in patients with COVID-19 found an overall rate of venous thrombotic events of 21%, with pulmonary emboli in 13%. 1 Rates were higher in patients admitted to an intensive care unit (ICU) with venous thrombosis in 31% and pulmonary emboli...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen